Cefpirome as empirical treatment for febrile neutropenia in patients with hematologic malignancies.
Cefpirome, a fourth generation cephalosporin, was administered during 154 episodes of febrile neutropenia in 106 patients. We assessed the clinical efficacy of cefpirome and its activity against isolated pathogens in neutropenic patients with hematologic malignancies. In addition, the pharmacokinetics and optimal dosing regimen of cefpirome during neutropenia were investigated.
Gert Jan
GJ
Timmers
Dannis G
DG
van Vuurden
Eleonora L
EL
Swart
Alberdina M
AM
Simoons-Smit
Peter C
PC
Huijgens
D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use* / Q000633:toxicity; D002511:Cephalosporins / Q000627:therapeutic use* / Q000633:toxicity; D005260:Female; D005334:Fever / Q000188:drug therapy*; D019337:Hematologic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D009503:Neutropenia / Q000188:drug therapy*; D000097572:Cefpirome
D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D000097572:Cefpirome